The Enteral Feeding Formulas Market size was valued at USD 6.04 billion in 2024 and is projected to grow to USD 15.5 billion by 2032, with CAGR of 9.90 % during the forecast period (2024 - 2032).
The enteral feeding formulas market is witnessing significant growth due to rising incidences of chronic diseases, an aging population, and advancements in healthcare technology. Enteral feeding involves delivering nutrition directly into the stomach or intestines of patients who cannot consume food orally, often due to severe illness, surgery, or neurological disorders. This market encompasses a variety of products, including standard, disease-specific, and specialty formulas designed to meet diverse nutritional needs.
Key drivers of market expansion include the increasing prevalence of conditions like cancer, gastrointestinal disorders, and stroke, which necessitate enteral feeding. Moreover, the growing geriatric population, more susceptible to chronic diseases and requiring nutritional support, fuels demand. Technological advancements have led to the development of more effective and patient-friendly feeding solutions, further propelling market growth.
Key Players
MRFR recognizes the following companies as the key players in the global Enteral Feeding Formulas Market Key Players— Reckitt Benckiser Group plc. (Mead Johnson), Abbott Laboratories, Danone SA (Nutricia), Fresenius SE & Co. KgaA (Fresenius Kabi AG), B. Braun Melsungen AG, Global Health Product Inc., Meiji Holdings Co. Ltd, Hormel Foods Corporation, Nestle SA, Kate Farms, Victus Inc., and Functional Formularies.
Market Segmentation
On the basis of product, the market is segmented into Standard Formulas and Disease-specific Formulas. The standard formulas segment was attributed to holding the largest market share in 2023. Standard formulae are designed to provide a balanced combination of macronutrients, micronutrients, and fiber and can be utilized for both short-term and long-term enteral feeding.
On the basis of application, the market is segmented into Oncology, Critical Care, Neurology, Diabetes, Gastroenterology, and Other Applications. The oncology segment was attributed to holding the largest market share in 2023. The majority of cancer patients have cancer cachexia, which results in increased protein turnover, insulin resistance, accelerated lipolysis with body fat loss, and loss of muscle mass, which impairs appetite and weight.
On the basis of end user, the market is segmented into Hospital, Home Care Agencies and Hospices, and Other End Users. The home care agencies segment was attributed to holding the largest market share in 2023.
Based on distribution channel, the global enteral feeding formulas market has been segmented into Hospitals, Retail Pharmacies, and Online Pharmacies. The hospitals segment was expected to hold the largest market share in 2023.
Regional Analysis
The global enteral feeding formulas market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe enteral feeding formulas market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The enteral feeding formulas market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World enteral feeding formulas market comprises of Middle East, Africa, and Latin America.
The North American regional sector maintained the largest market share for enteral feeding formulas because of a number of variables, including the aging population at a rapid pace, the rising preterm birth rate, and the rise in the number of people with chronic illnesses. Additionally, because enteral feeding formulas are becoming more and more popular in this age range, the aging population is predicted to fuel the market's expansion in this region.
Moreover, the Europe market has been persistently growing over the forecast period because chronic illnesses including cancer, neurological disorders, and digestive system issues, are becoming more common. According to estimates from the World Health Organization (WHO), cancer is the second leading cause of death in Europe, claiming approximately 1.3 million lives each year. Furthermore, 7.7 million cases of Alzheimer's disease (AD) are expected to occur in Europe. Another factor propelling market revenue growth in this region is the increasing prevalence of chronic disorders.
Additionally, Asia Pacific is anticipated to experience the quickest growth over the forecast period because of its sizable population, the rise of chronic illness patients, and the increased prevalence of malnutrition. Another key driver of regional growth is the rising rate of preterm births in the area. Moreover, the elderly population in this area is growing, and healthcare costs are rising
Related Report:
Wound Debridement Products Market
For more information visit at MarketResearchFuture
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Italiano
Russian
Romaian